<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006419</url>
  </required_header>
  <id_info>
    <org_study_id>R-2016-3001-61</org_study_id>
    <nct_id>NCT03006419</nct_id>
  </id_info>
  <brief_title>Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients</brief_title>
  <official_title>Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate that low dose (3 mg/kg total ) rATG (thymoglobulin) has similar efficacy (delayed
      graft function, slow graft function, biopsy proven acute rejection episodes, infections,
      hospitalizations, adverse events, graft loss and death) than Basiliximab induction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: The TAILOR study in living donor kidney transplantation demonstrated a 98% one
      year patient and graft survival and 91% and 83% at 5 years with rejection-free patients in
      93%. The cumulative dose of r ATG (thymoglobulin) was 5.29 mg / kg with 3% adverse effects
      and almost 50% steroid free at 12 months. Others have explored the benefit of low doses of r
      ATG (thymoglobulin) (3-5 mg / kg) against Basiliximab in low-risk population and demonstrated
      in living donor recipients with 8 year follow-up similar survival rates with a lower BPAR
      rate in rATG (thymoglobulin) (p &lt;0.05) and better serum creatinine in 3 and 5 years. The aim
      of the study was to demonstrate that low dose (3 mg/kg total ) rATG (thymoglobulin) has
      similar efficacy (delayed graft function, slow graft function, biopsy proven acute rejection
      episodes, infections, hospitalizations, adverse events, graft loss and death) than
      Basiliximab induction.

      Material and methods: Prospective randomized study of patients undergoing renal
      transplantation who wish to participate. 100 patients who meet the inclusion and exclusion
      criteria at the time of transplantation will be randomized

      Experimental and reference therapy:

      Group A: Induction with Basiliximab 20 mg IV day 0 and day 4 Group B: rATG (Thymoglobulin) 1
      mg / kg body weight per day for days 0, 1 and 2 up to a total dose of 3 mg / kg day.
      According to protocol administration, if there are conditions to delay administration
      (WBC&lt;2000 / mm3 and / or platelets &lt;75,000 / mm3) (17), administration may be postponed until
      day 7 posttransplant Posttransplant immunosuppression: Tacrolimus, mycophenolate mofetil and
      steroids

      Outcome measures (12 months) delayed graft function slow graft function biopsy proven acute
      rejection episodes infections hospitalizations adverse events graft loss death
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy proven acute rejection</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Acute rejection described by Banff category</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delayed graft function</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Dialysis during first week of transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow graft function</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Creatinine clearance &lt; 50% pretransplant during first week of transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>12 months following transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions</measure>
    <time_frame>12 months following transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Creatinine clearance measured by MDRD-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Return to dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Patient Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Group A (Basiliximab group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (Low-dose Thymoglobulin group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Standard induction therapy</description>
    <arm_group_label>Group A (Basiliximab group)</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Induction therapy</description>
    <arm_group_label>B (Low-dose Thymoglobulin group)</arm_group_label>
    <other_name>rATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female graft recipients older than 18 years of age.

          -  Informed consent to participate in the study.

          -  First living donor kidney transplant recipient.

          -  Negative pregnancy test if female participant

        Exclusion Criteria:

          -  Second or more kidney transplant.

          -  Multiple organ transplant recipients.

          -  ABO incompatibility or positive cross-over test prior to transplantation.

          -  Antibody Reactive Panel (PRA) &gt; 30%.

          -  Positive specific donor antibodies (DSA).

          -  Human immunodeficiency virus (HIV) positive patients.

          -  HBsAg or HCV positive.

          -  Severe lung disorders.

          -  Severe allergies receiving treatment that prevent patient's rRTAG administration.

          -  Leukocyte count below 2000 / mm3.

          -  Platelet count below 75,000 / mm3.

          -  History of malignant disease of any organ system (except skin basal cell carcinoma)
             within the last 5 years, regardless of local recurrence or metastasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Martinez-Mier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefe de División, UMAE 189, Veracruz, Veracruz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gustavo Martinez-Mier, MD</last_name>
    <phone>5212299295208</phone>
    <email>gmtzmier@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ernesto Soto-Miranda, MD</last_name>
    <phone>5212292106793</phone>
    <email>dr.ernestosoto@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umae Hospital Especialidades 14 Adolfo Ruiz Cortines</name>
      <address>
        <city>Veracruz</city>
        <zip>91897</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUSTAVO MARTINEZ-MIER, MD</last_name>
      <phone>5212299285208</phone>
      <email>gmtzmier@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ERNESTO SOTO-MIRANDA, MD</last_name>
      <phone>5212292106793</phone>
      <email>dr.ernestosoto@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S, Pankewycz O. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc. 2011 Mar;43(2):458-61. doi: 10.1016/j.transproceed.2011.01.035.</citation>
    <PMID>21440733</PMID>
  </reference>
  <reference>
    <citation>Schenker P, Ozturk A, Vonend O, Krüger B, Jazra M, Wunsch A, Krämer B, Viebahn R. Single-dose thymoglobulin induction in living-donor renal transplantation. Ann Transplant. 2011 Apr-Jun;16(2):50-8.</citation>
    <PMID>21716186</PMID>
  </reference>
  <results_reference>
    <citation>Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006 Nov 9;355(19):1967-77.</citation>
    <PMID>17093248</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaber AO, Matas AJ, Henry ML, Brennan DC, Stevens RB, Kapur S, Ilsley JN, Kistler KD, Cosimi AB; Thymoglobulin Antibody Immunosuppression in Living Donor Recipients Investigators. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation. 2012 Aug 27;94(4):331-7.</citation>
    <PMID>22850297</PMID>
  </results_reference>
  <results_reference>
    <citation>Hardinger KL, Schnitzler MA, Koch MJ, Labile E, Stirnemann PM, Miller B, Enkvetchakul D, Brennan DC. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation. 2006 May 15;81(9):1285-9.</citation>
    <PMID>16699456</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>induction</keyword>
  <keyword>thymoglobulin</keyword>
  <keyword>basiliximab</keyword>
  <keyword>acute rejection</keyword>
  <keyword>graft loss</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD sharing plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

